Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.
about
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisOff-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyAnti-IL-17 phase II data for psoriasis: A review.Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema.Differing effect of systemic anti psoriasis therapies on platelet physiology--a case report and review of literature.MiR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1α and VEGFA: Implications for psoriasis treatment.Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis.Diet and psoriasis, part I: Impact of weight loss interventionsCurrent consensus and update on psoriasis therapy: a perspective from the U.S.Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis.Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.Psoriasis treatment patterns of dermatologists in northeast Ohio.Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP).A Practical Approach to Home UVB Phototherapy for the Treatment of Generalized Psoriasis.The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in?Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasisClinical and histologic diagnostic guidelines for psoriasis: a critical review.Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life.Development of the US PSORIQoL: a psoriasis-specific measure of quality of life.Alcohol intake and risk of incident psoriasis in US women: a prospective study.Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis.European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.Biologics in the management of psoriasis.Validity of The Health Improvement Network (THIN) for the study of psoriasis.Vitamin D and psoriasis pathology in the Mediterranean region, Valencia (Spain)Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006.Genetic Epidemiology of PsoriasisModulating T cell responses for the treatment of psoriasis: a focus on efalizumab.Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.TNFalpha therapy in psoriatic arthritis and psoriasis.Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.Histological Stratification of Thick and Thin Plaque Psoriasis Explores Molecular Phenotypes with Clinical Implications.Determinants of quality of life in psoriasis patients: a cluster analysis of 50 patientsPrediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.Prevalence of chronic axial pain, inflammatory back pain, and spondyloarthritis in diagnosed psoriasis.Giving patients 'perceived control' over psoriasis: advice for optimizing the physician-patient relationship.Psoriasis and the new biologic agents: interrupting a T-AP danceInfliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.
P2860
Q26771682-03E6CB4F-895F-43F1-8C78-9975FF746E86Q26827714-120429BC-59BC-47CB-989E-9A30B8C8872BQ30760301-16469234-5D3C-4FF6-A249-1341EB0CC69CQ30828460-E9A84412-B2C2-46A1-BCFE-204714F6C33DQ33548150-9FB5FBAA-DB06-4CFB-A3DA-114C2C7C7713Q33554379-F4BF068B-A5A6-4EBC-A5FA-A7E20020CD07Q33710915-23BC84AA-A37E-4817-B8DC-DA25AD978AEAQ33786444-706E2E64-1684-4AD1-87A2-19AB6B732CA9Q33817878-39E40B08-C165-433B-A23E-1AD21245A125Q33822458-A7B12C22-5DB0-4975-A8E6-B49E4981ACE5Q33823950-2A94CEC7-4B53-4A72-9FB7-FB0B8A120E2BQ33895777-3FB75F3E-4A7C-47D0-8479-194D2F15A03FQ34071609-B642AE73-C0B8-4AD5-8ECB-ED32E07916B1Q34117369-A5FAFF4D-F232-42CC-BF22-7201872C94C7Q34156429-97CA6436-26F8-493F-9A36-6C6344D4D688Q34194956-61816C5F-99AC-433D-AD3B-2A11207B02C7Q34249689-6D4AA5A7-1B1E-45D8-B8B8-E60BDA24F64AQ34349903-5A17F1A5-B378-4A9F-B994-24B86AA62BD8Q34424519-5382C98C-2BEC-4E69-89EF-C967D07B79D9Q34473013-5DBDB413-3DE6-4E16-A30D-1F76864278FCQ34564453-A0CA886E-A454-4653-80C6-E5FBD30A0B14Q34570738-A194DAA8-D6A4-4319-A070-B08FCE08A00CQ34620257-F7199040-5880-4CC6-8515-BC7D58871D57Q34721703-DBDDF380-4202-4C4C-8177-D782DE2BDBD4Q34773007-BC748308-E0AC-4E17-8485-A78BA2A69C4CQ34785993-5A96B88E-BB87-4997-9D4C-285DCE56054BQ34845927-9406D9A7-3D65-4B8E-A505-7C0AEC956B6FQ35093640-F530A6E8-FDF7-46C8-AEED-02F768D3A416Q35131199-3B01A81E-1669-4CCA-BEA3-C888206526ABQ35554338-C4A6D647-55C4-47C0-80E4-03EF101752CEQ35555905-2D5D24C0-27E4-40B2-A5BC-1BC866E37530Q35606402-5E77989F-D161-40FE-99F3-D85AADD49316Q35636983-8CCA9512-5373-4BC4-BF34-1546B8BDA3ADQ35692116-08637426-508D-44C7-877E-34A651484A93Q35749056-92237B62-590D-4BDC-93E2-E9C963D7503CQ35760136-A05C6DC4-8E09-4B09-B71A-07753ABE28B5Q35809261-E3C4AFFB-CACA-4643-8800-E4968B3BB8EBQ35809501-0260441B-BF4E-4382-9114-8C1FFE5D37DAQ35813465-3AEF8BE5-7685-4347-B697-5E292615E794Q35819025-E2E0C025-A575-49D8-BF3D-FB3C08917DA0
P2860
Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Population-based epidemiologic ...... on quality of life assessment.
@en
Population-based epidemiologic ...... on quality of life assessment.
@nl
type
label
Population-based epidemiologic ...... on quality of life assessment.
@en
Population-based epidemiologic ...... on quality of life assessment.
@nl
prefLabel
Population-based epidemiologic ...... on quality of life assessment.
@en
Population-based epidemiologic ...... on quality of life assessment.
@nl
P1433
P1476
Population-based epidemiologic ...... on quality of life assessment.
@en
P2093
P304
P356
10.1016/S0733-8635(05)70376-4
P577
1996-07-01T00:00:00Z